IL17A and gastric cancer: Similarly, treatment of quiescent gastric cancer stem cells with IL‐17 also results in EMT‐like changes including E‐cadherin loss, de novo vimentin acquisition, and increased migratory and invasive properties (Jiang et al., 2017) and associates with STAT3 phosphorylation.